Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.

A retroviral vector was designed to express toxic proteins only in the presence of the HIV-1 Rev and/or Tat protein(s). The design of this vector incorporates an HIV-specific expression cassette that consists of three elements: the U3R region of the HIV-1 IIIB LTR provides the promoter and Tat-responsive element, a modified intron derived from the human c-src gene facilitates the splicing of inserted genes, and the HIV-1 RRE region enhances the transport of unspliced mRNAs. To further limit potential readthrough transcription, the expression cassette was inserted in the reverse transcriptional orientation relative to the retroviral vector LTR. Three different genes, interferon alpha2, diphtheria toxin (DT-A), and cytosine deaminase, were inserted into this vector. Tat and Rev inducibility was demonstrated directly by a >300-fold induction of interferon production and functionally by a decrease in colony-forming units when a Tat and Rev expression vector was titered on HeLa cells harboring the inducible DT-A cassette. The Tat-inducible cytosine deaminase gene was tested in the Sup-T1 T cell line and shown to inhibit HIV-1 production only when engineered cells were grown in the presence of 5-fluorocytosine. To test the ability of this system to inhibit HIV-1 infection in bulk PBL cultures, a series of transduction and challenge experiments was initiated with both the interferon and DT-A vectors. Protection against infection was documented against three HIV strains in PBLs. Last, the interferon and DT-A vectors were compared with a vector encoding a transdominant Rev protein and were shown to mediate equal or greater inhibition of HIV-1.

[1]  R. Morgan,et al.  Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. , 2000, Human gene therapy.

[2]  R. Morgan,et al.  Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. , 2000, Human gene therapy.

[3]  Richard A. Morgan,et al.  Gene Therapy for Infectious Diseases , 1998, Clinical Microbiology Reviews.

[4]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[6]  D. Littman,et al.  Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene , 1997, Journal of virology.

[7]  S. Matsushita,et al.  Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. , 1996, Human gene therapy.

[8]  R. Morgan,et al.  Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. , 1996, Human gene therapy.

[9]  G. Nabel,et al.  Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Mullen,et al.  Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. , 1996, Cancer research.

[11]  P. Narciso,et al.  Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. , 1996, AIDS research and human retroviruses.

[12]  M. Daucher,et al.  Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. , 1995, AIDS research and human retroviruses.

[13]  T. Curiel,et al.  HIV-regulated diphtheria toxin A chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line U937. , 1995, Human gene therapy.

[14]  R. Morgan,et al.  Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes , 1995, Journal of virology.

[15]  B. Jacobsson,et al.  Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. , 1995, AIDS research and human retroviruses.

[16]  I. Lowy,et al.  Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. , 1995, Virology.

[17]  P. Pitha,et al.  Inhibition of human immunodeficiency virus type 1 replication by a Tat-activated, transduced interferon gene: targeted expression to human immunodeficiency virus type 1-infected cells , 1995, Journal of virology.

[18]  R. Morgan,et al.  Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. , 1994, Human gene therapy.

[19]  M J Sheehy,et al.  Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. Anderson,et al.  Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1. , 1994, AIDS research and human retroviruses.

[21]  R. Blaese,et al.  Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. , 1994, Cancer research.

[22]  D. Pennington,et al.  Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Ghosh,et al.  Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-regulated diphtheria toxin A chain gene. , 1993, Human gene therapy.

[24]  J. Lisziewicz,et al.  Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Daucher,et al.  Factors affecting retroviral vector function and structural integrity. , 1993, Virology.

[26]  O. Yamada,et al.  A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Zhou,et al.  Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes , 1993, Journal of virology.

[28]  J. Ojwang,et al.  Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Malim,et al.  Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication , 1992, The Journal of experimental medicine.

[30]  T. Curiel,et al.  Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. , 1992, Human gene therapy.

[31]  M. Feinberg,et al.  Intracellular immunization: trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication. , 1992, AIDS research and human retroviruses.

[32]  A. Panganiban,et al.  Human immunodeficiency virus vectors for inducible expression of foreign genes , 1992, Journal of virology.

[33]  B. Sullenger,et al.  Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation , 1991, Journal of virology.

[34]  S. Read,et al.  Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme , 1991, Journal of virology.

[35]  S. Astrin,et al.  Human immunodeficiency virus induction of malignant transformation in human B lymphocytes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Vivés,et al.  Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1 , 1991 .

[37]  S. Salahuddin,et al.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.

[38]  A. Nienhuis,et al.  Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Berkhout,et al.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target , 1989, Cell.

[40]  M. Mathews,et al.  HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation , 1989, Cell.

[41]  D. Baltimore,et al.  HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus , 1989, Cell.

[42]  D. Bednarik,et al.  Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Malim,et al.  Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes , 1988, Nature.

[44]  J. Ghrayeb,et al.  Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis. , 1987, Science.

[45]  M. Bender,et al.  Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region , 1987, Journal of virology.

[46]  D. Capon,et al.  Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein , 1987, Cell.

[47]  M. Feinberg,et al.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA , 1986, Cell.

[48]  J. Sodroski,et al.  A second post-transcriptional trans-activator gene required for HTLV-III replication , 1986, Nature.

[49]  V. Avramis,et al.  Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. , 1995, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.

[50]  G. Th The International Retrovirology Association Starts a New Venture with JAIDS & HR of Raven Press , 1995 .

[51]  B. Fox,et al.  A molecular genetic intervention for AIDS--effects of a transdominant negative form of Rev. , 1994, Human gene therapy.

[52]  D. Klatzmann,et al.  Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. , 1992, Proceedings of the National Academy of Sciences of the United States of America.